Pasithea Therapeutics Corp Stock Today
| KTTA Stock | USD 1.24 0.06 5.08% |
PerformanceVery Weak
| Odds Of DistressLow
|
Pasithea Therapeutics is trading at 1.24 as of the 24th of March 2025, a 5.08% increase since the beginning of the trading day. The stock's open price was 1.18. Pasithea Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of September 2021 | Category Healthcare | Classification Health Care |
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.27 M outstanding shares of which 26.66 K shares are now shorted by private and institutional investors with about 0.0 trading days to cover. More on Pasithea Therapeutics Corp
Moving together with Pasithea Stock
Moving against Pasithea Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pasithea Stock Highlights
| CEO Director | Tiago MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPasithea Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pasithea Therapeutics' financial leverage. It provides some insight into what part of Pasithea Therapeutics' total assets is financed by creditors.
| |||||
Pasithea Therapeutics Corp (KTTA) is traded on NASDAQ Exchange in USA. It is located in 1111 Lincoln Road, Miami Beach, FL, United States, 33139 and employs 8 people. Pasithea Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.57 M. Pasithea Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.27 M outstanding shares of which 26.66 K shares are now shorted by private and institutional investors with about 0.0 trading days to cover.
Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pasithea Therapeutics Probability Of Bankruptcy
Ownership AllocationPasithea Therapeutics holds 19.08 pct. of its outstanding shares held by insiders and 6.09 pct. owned by third-party entities.
Check Pasithea Ownership Details
Pasithea Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-12-31 | 61 K | |
| Ubs Group Ag | 2024-12-31 | 12.9 K | |
| Tower Research Capital Llc | 2024-12-31 | 1.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1000 | |
| Royal Bank Of Canada | 2024-12-31 | 250 | |
| Jpmorgan Chase & Co | 2024-12-31 | 150 | |
| Bank Of America Corp | 2024-12-31 | 8.0 | |
| Adar1 Capital Management Llc | 2024-09-30 | 0.0 | |
| Fmr Inc | 2024-09-30 | 0.0 |
Pasithea Therapeutics Historical Income Statement
Pasithea Stock Against Markets
Pasithea Therapeutics Corporate Management
| Yassine Bendiabdallah | COO Clinics | Profile | |
| MD BA | Ex CoFounder | Profile | |
| Tiago Marques | CEO Director | Profile | |
| Daniel Schneiderman | Chief Officer | Profile | |
| Graeme Currie | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.